David Dalstrom, MD
Foot and Ankle Surgery · Seattle, WANPI 1942333075
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $386,946 of the $490,986 with a category attached, or 78.8%. Stryker accounts for 94.5% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $130,376, more than ten times the $3,658 reported in 2019. Among foot and ankle surgery clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 465 payments — averaging $1055.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$464K
- Arthrex$23K
- Impactortho, Inc.$2K
- Sportstek Medical, Inc$2K
- Elevate Surgical Co$115
- Bioventus LLC$90
- plus $65 from 3 others
Across 16 payments — averaging $1261.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Stryker$14K
- Arthrex$6K
What the payments were for
- Consulting fees$386,94679%
- Speaking & faculty fees$21,4004%
- Travel & lodging$67,35514%
- Food & beverage$12,3303%
- Education$2,9551%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker(2 entities) | 413 | $463,985 |
| Arthrex | 34 | $22,774 |
| Impactortho, Inc. | 3 | $2,412 |
| Sportstek Medical, Inc | 5 | $1,546 |
| Elevate Surgical Co | 2 | $115 |
| Bioventus LLC | 5 | $90 |
| Nevro Corp. | 1 | $33 |
| Acell, Inc. | 1 | $17 |
| Lemaitre Vascular, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROstep$211,590
- PROPHECY$92,008
- INFINITY$81,463
- INBONE$49,173
- ORTHOLOC 2 LAPIFUSE$45,805
- INVISION$44,100
- PROSTEP MICA$36,788
- AUGMENT INJECTABLE$16,056
- EASYFUSE$12,375
- EASY CLIP$12,375
- AXSOS$11,006
- HOFFMANN$11,006
- T2$8,775
- PRIME SERIES$6,187
- INFINITY ADAPTIS$4,298
- VARIAX$3,356
- ORTHOLOC 3DI$2,700
- ORTHOLOC 3DI CROSSCHECK$2,700
- GAMMA$2,231
- ANCHORAGE$1,350
How this compares
$490,986 in reported general payments places this provider in the 95th percentile of 203 foot and ankle surgery providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other foot and ankle surgery in Seattle
- Adam AlbabaSeattle$46K
- Stephen BenirschkeSeattle$45K
- Kivanc AtesokSeattle$16K
- Adam SangeorzanSeattle$12K
- Christopher PriceSeattle$11K
- Kenneth ChinSeattle$10K
- Gregory GrantSeattle$6K
- Anthony LoSeattle$6K
- Maduwilla SilvaSeattle$6K
- Salvatore RizzoSeattle$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.